These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36198531)

  • 1. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
    Nagafuji K
    Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
    Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
    Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
    Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
    J Infect Chemother; 2023 Mar; 29(3):274-280. PubMed ID: 36442827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
    Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
    Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Ali H; Ngo D; Aribi A; Arslan S; Dadwal S; Marcucci G; Nakamura R; Forman SJ; Chen J; Al Malki MM
    Transplant Cell Ther; 2021 Nov; 27(11):938.e1-938.e6. PubMed ID: 34274492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation.
    Chaekal OK; Gomez-Arteaga A; Chen Z; Soave R; Shore T; Mayer S; Phillips A; Hsu JM; Drelick A; Kodiyanplakkal RPL; Plate M; Satlin MJ; van Besien K
    Transplant Cell Ther; 2022 Sep; 28(9):618.e1-618.e10. PubMed ID: 35724850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
    Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
    Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
    Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
    Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
    Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
    Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study.
    Ngo D; Chen J; Tinajero J; Aribi A; Arslan S; Marcucci G; Nakamura R; Al Malki MM; Forman SJ; Dadwal S; Ali H
    Stem Cell Res Ther; 2023 Apr; 14(1):95. PubMed ID: 37072867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients.
    Shem-Tov N; Yerushalmi R; Danylesko I; Litachevsky V; Levy I; Olmer L; Lusitg Y; Avigdor A; Nagler A; Shimoni A; Rahav G
    Br J Haematol; 2022 Feb; 196(4):884-891. PubMed ID: 34713441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
    Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
    Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation.
    Barabino L; Galitzia A; Murru R; Caocci G; Targhetta C; Greco M; Angioni G; Mulas O; Vacca A; Piras E; Frau V; Costa A; La Nasa G
    Eur Rev Med Pharmacol Sci; 2022 Dec; 26(23):8984-8989. PubMed ID: 36524517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
    Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
    Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
    Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
    Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
    Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
    Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
    Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.